These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34875838)

  • 1. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
    Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
    Ceska Slov Farm; 2021; 70(5):164–171. PubMed ID: 34875838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
    Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
    Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bipolar Distribution of Minimum Inhibitory Concentration of Q203 Across Mycobacterial Species.
    Wang J; Jing W; Shi J; Huo F; Shang Y; Wang F; Chu N; Pang Y
    Microb Drug Resist; 2021 Aug; 27(8):1013-1017. PubMed ID: 33646044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of mycobacterial CIII
    Yanofsky DJ; Di Trani JM; Król S; Abdelaziz R; Bueler SA; Imming P; Brzezinski P; Rubinstein JL
    Elife; 2021 Sep; 10():. PubMed ID: 34590581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB).
    Lee BS; Pethe K
    Expert Opin Investig Drugs; 2022 Feb; 31(2):139-144. PubMed ID: 35034512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
    Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
    Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.
    Kang S; Kim RY; Seo MJ; Lee S; Kim YM; Seo M; Seo JJ; Ko Y; Choi I; Jang J; Nam J; Park S; Kang H; Kim HJ; Kim J; Ahn S; Pethe K; Nam K; No Z; Kim J
    J Med Chem; 2014 Jun; 57(12):5293-305. PubMed ID: 24870926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
    Pethe K; Bifani P; Jang J; Kang S; Park S; Ahn S; Jiricek J; Jung J; Jeon HK; Cechetto J; Christophe T; Lee H; Kempf M; Jackson M; Lenaerts AJ; Pham H; Jones V; Seo MJ; Kim YM; Seo M; Seo JJ; Park D; Ko Y; Choi I; Kim R; Kim SY; Lim S; Yim SA; Nam J; Kang H; Kwon H; Oh CT; Cho Y; Jang Y; Kim J; Chua A; Tan BH; Nanjundappa MB; Rao SP; Barnes WS; Wintjens R; Walker JR; Alonso S; Lee S; Kim J; Oh S; Oh T; Nehrbass U; Han SJ; No Z; Lee J; Brodin P; Cho SN; Nam K; Kim J
    Nat Med; 2013 Sep; 19(9):1157-60. PubMed ID: 23913123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis.
    Lupien A; Foo CS; Savina S; Vocat A; Piton J; Monakhova N; Benjak A; Lamprecht DA; Steyn AJC; Pethe K; Makarov VA; Cole ST
    PLoS Pathog; 2020 Jan; 16(1):e1008270. PubMed ID: 31971990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
    Urban M; Šlachtová V; Brulíková L
    Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting the synthetic lethality between terminal respiratory oxidases to kill
    Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K
    Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of
    Zhou S; Wang W; Zhou X; Zhang Y; Lai Y; Tang Y; Xu J; Li D; Lin J; Yang X; Ran T; Chen H; Guddat LW; Wang Q; Gao Y; Rao Z; Gong H
    Elife; 2021 Nov; 10():. PubMed ID: 34819223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on perchlozone, an anti-tuberculosis drug from the Russian Federation.
    Malík I; Čižmárik J; Pecháčová M
    Ceska Slov Farm; 2020; 69(5-6):203-210. PubMed ID: 33736445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.
    Sorayah R; Moraski GC; Barkan D; Pethe K
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0096421. PubMed ID: 34543090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of
    Chauhan P; van der Meulen SA; Simões Caetano JM; Goojani HG; Botman D; van Spanning R; Lill H; Bald D
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.
    Lu P; Asseri AH; Kremer M; Maaskant J; Ummels R; Lill H; Bald D
    Sci Rep; 2018 Feb; 8(1):2625. PubMed ID: 29422632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties.
    Liu R; Marshall K; Ma R; Lien Thi Pham K; Shetye G; Liu Z; Cho S; Jeong H; Franzblau SG; Moraski GC; Miller MJ
    Bioorg Chem; 2022 Nov; 128():106074. PubMed ID: 35987188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally-Occurring Polymorphisms in QcrB Are Responsible for Resistance to Telacebec in
    Sorayah R; Manimekalai MSS; Shin SJ; Koh WJ; Grüber G; Pethe K
    ACS Infect Dis; 2019 Dec; 5(12):2055-2060. PubMed ID: 31599569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.